Vascular lesions are intended to be the following:
Telangiectases of the face, couperose, erythrosis, rosacea, neovascularizations, superficial telangiectases of the limbs, matting, port wine spots (PWS), venous lakes, nevus flammeus, senile, star-and cherry-like angiomas, varicose veins, spider veins.
The green visible wavelength of 532 nm, along with the yellow 577 nm, has always been recognized as the most suitable for oxyhaemoglobin absorption.
The high power, extensive absorption and extreme superficial action of its wavelength make the Eufoton®LASEmaR® 500 LBO green laser ideal for treating all the superficial pigmented and vascular lesions characterized by a thin and atrophic wall.
Since the foundation of Eufoton®, the 808 nm wavelength of the various versions of the LASEmaR® 800 has historically been the first to be developed in the vascular field. For the company it is therefore a gold standard for dermatology and phlebology for various vascular solutions, documented by the numerous consolidated operating protocols in almost 20 years of application experience.
Its main feature is high affinity for bone chromophores and deoxyhemoglobin and a very low interference from tissue water.
The LASEmaR® 800 is therefore indicated in vascular dermatology for the treatment of all major telangiectasias, including those on the face (i.e. nostrils) where all visible wavelengths (blue, green, yellow lasers or pulsed light) have difficulty and penetration limits. As documented by years of experience, telangiectases on the lower limbs respond well to percutaneous treatment with LASEmaR® 800, especially in select cases that are also associated with previous sclerotherapy. For vasular dermatologists who also deal with phlebology, it is important to present FLEBOLASER, a combined exo/endo dermal method with LASEmaR® 800 for the combined treatment of spider and reticular veins of the legs.
Percutaneous treatment with LASEmaR® 800 is ideal for treating small isolated and superficial ectases (approximately 1 mm in diameter); for cases of micro vessels subject to mixed or deep reflux (more than 1 mm in diameter), where sclerotherapy seemed to be the first option, transdermal treatment can work in synergy with an endo-perivenous treatment by means of optical microfibers, in order to achieve better and faster results without the typical chemical limit of the sclerosing drug.
Transdermal or endo-perivenous laser treatment of telangiectasias combined with a suitable skin cooling system is always preferred over chemical sclerosis in patients with previous systemic or local allergic manifestations, pigmentations, matting and those who have a phobia for needles.Likewise, the endo-perivenous method with LASEmaR® 800 proposed for reticular, perforator and trunk varicose veins is ideal in cases where surgical phlebectomy would cause undesired scarring due to keloid proneness or where chemical sclerotherapy would produce aesthetically unpleasant depigmentations.
Venous Lake treatment with LASEmaR® 800 - Courtesy of Torre MD
LASEmaR® 940 utilizes the 940 nm wavelength which is a valid and effective alternative to the 808 nm wavelength for transdermal treatment of spider veins because it has a higher haemoglobin absorption; due to its activity with water, it cannot however be used for endo-perivenous treatment
Do you need help? Fill in the form and we will help you solve it.
Some of the information contained in this website are exclusively directed to healthcare professionals, in compliance with art. 21 of the Decree n. 46 of February 24th, 1997 and subsequent modifications and integrations, and the Guidelines of the Italian Ministry of Health of March 28th, 2013.
The possibility to continue browsing and access to the content relating to products, technical descriptions and commercial offers is subject to the statement made by the user, under his own responsibility, to be a healthcare professional. The simple visitors will be redirected to institutional page of Eufoton.
ABILITA or DISABILITA.
By pressing Continue I declare under my own responsibility to be a healthcare provider and continuing to browse I declare to accept the cookie information.